• Explore /
  • Poster
  • / Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).

Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).

Abstract Video & Slides Poster

Authors

Himisha Beltran

Himisha Beltran

Dana-Farber Cancer Institute, Boston, MA

Himisha Beltran , Melissa Lynne Johnson , prantesh jain , Erin L. Schenk , Rachel E. Sanborn , Jonathan Robert Thompson , Afshin Dowlati , Hirva Mamdani , Rahul Raj Aggarwal , Banmeet S Anand , Ann W. Gramza , Noura J. Choudhury

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT04471727

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 8090)

DOI

10.1200/JCO.2024.42.16_suppl.8090

Abstract #

8090

Poster Bd #

352

Abstract Disclosures

Similar Posters

First Author: Jiwon Lee

First Author: Meiqi Shi

First Author: Melissa Lynne Johnson

First Author: Aung Naing